` PBP (Probiotec Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

PBP
vs
S&P/ASX 300

Over the past 12 months, PBP has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's 9% growth.

Stocks Performance
PBP vs S&P/ASX 300

Loading
PBP
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
PBP vs S&P/ASX 300

Loading
PBP
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
PBP vs S&P/ASX 300

Loading
PBP
S&P/ASX 300
Add Stock

Competitors Performance
Probiotec Ltd vs Peers

S&P/ASX 300
PBP
LLY
JNJ
NOVO B
ROG
Add Stock

Probiotec Ltd
Glance View

Market Cap
242.3m AUD
Industry
Pharmaceuticals

Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-11-14. The firm owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. The Company’s products are manufactured on behalf of a range of clients, including international companies. The company also owns Multipack-LJM business, a contract packer, providing packing services for a range of pharmaceutical, consumer healthcare, cosmetics and food, and beverage companies. The firm subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Biotech Pharmaceuticals Australia Pty Ltd, Biotech Pharmaceuticals Pty Ltd, Probiotec (NSW) Pty Ltd, Australian Dairy Proteins Pty Ltd, Milton Pharmaceuticals Pty Ltd and Willie Labs Generics Pty Ltd.

PBP Intrinsic Value
4.06 AUD
Undervaluation 27%
Intrinsic Value
Price
Back to Top